Mar 17 2026
9th Cir. 24-2180 Unanimous

United States of America ex rel. ADVENTIST HEALTH SYSTEM OF WEST v. ABBVIE INC.

The Ninth Circuit reversed the dismissal of a qui tam action alleging drug manufacturers violated the False Claims Act by inflating prices under the Section 340B Program. The court held that while the Supreme Court barred direct private suits to enforce Section 340B, the False Claims Act provides an independent cause of action for fraud against the government that is not precluded by that limitation.

Mar 16 2026
9th Cir. 2:23-cv-10363-RGK-RAO Unpublished

Keyubba Bowman; Rashon Bowman v. Novad Management Consulting, LLC; ISN Corporation; United States Department of Housing and Urban Development; Does, 1 through 50, inclusive

The Ninth Circuit affirmed the district court's dismissal of the Bowmans' claims under the Real Estate Settlement Procedures Act and the Fair Debt Collection Practices Act. The appellate panel held that the lower court properly denied the plaintiffs' motions for default judgment and a continuance based on the specific legal standards governing those requests.

Mar 4 2026
9th Cir. 3:21-cv-05854-BHS Unpublished

WILLIAM HUNT, Jr v. MEDTRONIC USA, INC

The Ninth Circuit affirmed the district court's grant of summary judgment against a plaintiff alleging harm from a malfunctioning medical device. The court held that the plaintiff failed to provide evidence of public impact for his consumer protection claim and lacked necessary expert testimony for his negligence claim.

Mar 2 2026
1st Cir. 25-1258 Panel Decision

City of Boston v. OptumRx, Inc.

The First Circuit affirmed the dismissal of Boston's public nuisance lawsuit against pharmacy benefit managers, ruling the claim was barred by the three-year statute of limitations. The court held that the City had actual knowledge of the alleged wrongdoing well before the filing deadline and failed to plead a continuing nuisance theory under Massachusetts law.

Mar 2 2026
1st Cir. 25-1265 Panel Decision

City of Boston v. OptumRx, Inc.

The First Circuit affirmed the dismissal of Boston's public nuisance lawsuit against pharmacy benefit managers, ruling the claims were barred by the three-year statute of limitations. The court held that the City had actual knowledge of the alleged wrongdoing well before 2021, precluding tolling under the fraudulent concealment doctrine.

Jan 2 2026
United States Court… 25-5135 Panel Decision

Twardy v. Ocwen Financial Corporation

The D.C. Circuit affirmed the dismissal of a consumer protection lawsuit, ruling that plaintiffs lacked a private right of action to enforce the Consumer Financial Protection Act. The court further held that the CFPB and D.C. Attorney General were not required parties and that state law claims fell outside the court's supplemental jurisdiction.

Jul 30 2024
United States Court… 21-7127 Panel Decision

Exxon Mobil Corporation v. Corporación CIMEX, S.A. (Cuba), Corporación CIMEX, S.A. (Panama), and Unión Cuba-Petróleo

The D.C. Circuit held that the Cuban Liberty and Democratic Solidarity Act does not independently strip foreign sovereigns of immunity, leaving the Foreign Sovereign Immunities Act as the exclusive basis for jurisdiction. The court vacated the district court's ruling and remanded for further fact-finding on whether the defendants' current commercial operations in the United States satisfy the FSIA's commercial-activity exception.